The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Rebecca Sutphen, MD
Chief medical officer and co-founder, InformedDNA
Table of Contents

YOU MAY BE INTERESTED IN

Health Equity

ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.
By Jacquelyn Cobb
Byline
Rebecca Sutphen, MD
Chief medical officer and co-founder, InformedDNA
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account